What Is Thymosin Alpha-1?

Thymosin Alpha-1 (also called thymalfasin) is a naturally occurring 28-amino-acid peptide derived from the thymus gland. It was originally isolated from thymosin fraction 5 (a thymus extract) by Allan Goldstein and colleagues at the National Cancer Institute in the 1970s. It is acetylated at the N-terminus, a modification that protects it from enzymatic degradation and contributes to its activity. In the body, it is produced primarily in thymic epithelial cells.

The thymus gland produces peptides that regulate T-cell maturation. Thymosin Alpha-1 is the most potent and best-characterized of these, and its biological role is to promote T-cell development and activity. Thymic function — and with it, Thymosin Alpha-1 secretion — declines substantially with age. The thymus begins involuting in early adulthood and is largely replaced by fat tissue by the sixth decade. This age-related decline has driven interest in Thymosin Alpha-1 as an immune support compound for older adults and immunocompromised patients.

Thymosin Alpha-1 is sold as Zadaxin (manufactured by SciClone Pharmaceuticals) and is approved in approximately 35 countries, including China, Italy, and many others in Asia, Europe, and South America, for the treatment of hepatitis B, hepatitis C (as an adjuvant to interferon), malignant melanoma, and as an adjuvant to chemotherapy in cancer patients. It is not FDA-approved, and it is not EMA-approved. Its approval status outside the US makes it unusual in this group — it has more international regulatory history than any other compound on this site.

What Does the Research Say?

Evidence level: Strong — Thymosin Alpha-1 has the most extensive clinical trial record of any peptide on this site. Multiple Phase II and Phase III randomized controlled trials have been published for hepatitis B, hepatitis C, and oncology adjuvant indications. The compound is approved in over 35 countries on the basis of this evidence. The absence of FDA approval reflects the economics and regulatory pathway of the specific drug developer, not a gap in the evidence base.

Mechanism

Thymosin Alpha-1's primary mechanism is enhancement of T-cell maturation and function. Specifically, it promotes differentiation of T-cell precursors into functional T helper (Th1) cells, upregulates expression of MHC class I and II molecules on dendritic cells and macrophages, and increases secretion of pro-inflammatory cytokines (IFN-gamma, IL-2) that drive antiviral and antitumor immune responses. It also supports regulatory T cell activity, which prevents excessive immune activation — an important consideration for a compound used in autoimmune-adjacent contexts.

The antiviral mechanism is particularly well-characterized. Thymosin Alpha-1 induces production of type I interferons (IFN-alpha, IFN-beta), which have direct antiviral effects and amplify immune cell responses to infected cells. This is the main mechanism behind its efficacy in hepatitis B and C treatment.

In cancer contexts, the mechanism is T-cell reactivation: tumors often suppress antitumor immunity through regulatory pathways. Thymosin Alpha-1 restores T-cell responsiveness, particularly in patients whose immune function has been impaired by chemotherapy or the tumor microenvironment.

Animal Studies

Animal studies in mice and rats have documented the core immunological effects: T-cell expansion and activation, enhanced viral clearance in animal infection models, reduced tumor growth when combined with other treatments, and reduced immunosuppression after chemotherapy. These studies provided the mechanistic foundation for clinical development.

Human Studies

Thymosin Alpha-1 has a clinical trial record that substantially exceeds what is typical for peptides in this category.

For hepatitis B, multiple randomized, placebo-controlled trials have been conducted across multiple countries. A 1999 multicenter Phase III trial by Mutchnick MG and colleagues in the US published in the Journal of Viral Hepatitis enrolled patients with chronic hepatitis B and showed improvements in HBeAg seroconversion and HBV DNA levels compared to placebo. Additional trials from Chinese and Italian groups have been published with generally consistent findings. A meta-analysis of the hepatitis B evidence has supported the use of Thymosin Alpha-1 as adjuvant to antiviral therapy for HBV.

For hepatitis C, combination studies with interferon-alpha have documented improved sustained virological response rates when Thymosin Alpha-1 is added to interferon therapy, particularly in patients who don't respond well to interferon alone. Rasi G and colleagues published early work in this area.

For cancer adjuvant use, studies in hepatocellular carcinoma, lung cancer, and melanoma have examined Thymosin Alpha-1 alongside chemotherapy, documenting reduced treatment-related infections and some data on immune reconstitution after treatment.

During the COVID-19 pandemic, multiple Chinese clinical trials examined Thymosin Alpha-1 in severe patients, given the compound's established immunomodulatory profile and availability in China. Several studies showed reduced mortality and faster recovery in treated versus control groups. These studies were conducted under emergency conditions, had methodological limitations, and have not changed international guidelines, but they add to the human data record.

This clinical record is real. The absence of FDA approval reflects business and regulatory pathway decisions by the drug developer, not a judgment that the evidence is insufficient.

Community and Anecdotal Reports

Community use of Thymosin Alpha-1 in the United States is concentrated among people with immune system concerns: HIV/AIDS, cancer survivors, people with chronic infections, and those with age-related immune decline. The most consistent reports are of improved immune resilience — fewer infections, faster recovery when sick, improved response to vaccinations.

The longevity community uses it for age-related immunosenescence, on the premise that declining thymic function contributes to immune aging and that Thymosin Alpha-1 can partially compensate. Some users report taking it periodically around times of heightened infection risk or after periods of stress that suppress immune function.

Common Uses

Immune Support and Immunosenescence

The most common community use in the United States. The mechanism — restoring Th1 function and T-cell activity — is directly relevant to the age-related decline in adaptive immunity. The evidence for this specific application (healthy aging adults) is not as strong as for the hepatitis and cancer adjuvant indications, but the mechanism is the same.

Hepatitis B and C Adjuvant Therapy

The most evidence-backed application. Multiple RCTs show benefit when Thymosin Alpha-1 is added to antiviral therapy or interferon regimens. This is an approved indication in dozens of countries. In the United States, where it is not approved, this would be off-label use.

Cancer Adjuvant

Adjuvant immune support during chemotherapy has clinical trial support, particularly for reducing infection rates and supporting immune reconstitution after treatment. Some oncologists in countries where Zadaxin is available use it in this context.

Infection Recovery and Sepsis

Some evidence from clinical studies in sepsis and severe infections suggests Thymosin Alpha-1 may reduce mortality in severely immunocompromised patients. This is less established than the viral hepatitis data but represents a clinically interesting area of ongoing research.

Delivery Methods

Subcutaneous Injection

Subcutaneous injection is the standard and only validated route. The approved Zadaxin formulation is a lyophilized powder reconstituted for subcutaneous injection. Oral bioavailability is essentially zero due to gastrointestinal degradation. The peptide's 28-amino-acid size makes intranasal delivery unlikely to achieve meaningful systemic absorption without specialized formulations.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

Thymosin Alpha-1 has the most extensive clinical safety record of any peptide on this site. In the hepatitis B and C trials, side effects were generally mild: injection site reactions, occasional fatigue, and infrequent low-grade fever. No serious adverse events attributed to Thymosin Alpha-1 were reported in the pivotal trials.

Community reports are consistent with the clinical record. Injection site reactions are the most common complaint. Some users report transient fatigue, particularly with initial injections, which they attribute to immune activation. Serious adverse events are not reported.

One theoretical concern with any immunostimulatory compound is autoimmune activation. Thymosin Alpha-1 increases T-cell activity; in someone with a predisposition to autoimmune disease, that activation could theoretically be problematic. This has not been documented as a clinical problem in the trial record, and Thymosin Alpha-1's support for regulatory T cells provides some theoretical counterbalance. Still, people with active autoimmune disease should discuss this with their physician.

Thymosin Alpha-1 (thymalfasin, Zadaxin) is approved in over 35 countries and is a recognized pharmaceutical product in those jurisdictions. It is not FDA-approved and is not EMA-approved. In the United States it is sold as a research compound, not a pharmaceutical.

Thymosin Alpha-1 is one of the 12 peptides targeted in the current reclassification process. For details on what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Frequently Asked Questions

The FDA approval process requires a specific drug developer to conduct trials and submit a New Drug Application in the United States. Thymosin Alpha-1's developer pursued approval in Asian and European markets where regulatory pathways and market dynamics were more favorable. The evidence base would likely support FDA approval if a developer pursued it — the compound is not FDA-approved because no one has funded the regulatory process in the US, not because the evidence failed.

No. Thymosin Alpha-1 and Thymosin Beta-4 are both thymic peptides but are structurally and functionally distinct. Thymosin Alpha-1 regulates T-cell maturation and immune activation. Thymosin Beta-4 (and TB-500) regulate actin dynamics and tissue repair. They come from the same original thymosin fraction 5 extract but are completely different molecules.

The mechanism is directly relevant: the thymus involutes with age, T-cell function declines, and Thymosin Alpha-1 supports T-cell maturation and activity. Whether supplementing Thymosin Alpha-1 meaningfully offsets immunosenescence in healthy older adults has not been studied in clinical trials. The immune restoration seen in hepatitis and cancer patients represents a different clinical context. The mechanism is plausible; the evidence for healthy aging populations is absent.

Different mechanisms, different evidence bases, different applications. Thymosin Alpha-1 is an adaptive immunity modulator operating through T-cell pathways. LL-37 is an innate immunity antimicrobial peptide. KPV is an anti-inflammatory peptide acting through melanocortin receptors. They address different parts of immune function. Thymosin Alpha-1 has substantially more clinical trial data than either of the others.

Learn More

Sources

  1. Mutchnick MG, Lindsay KL, Schiff ER, et al. "Thymosin alpha 1 treatment of patients with chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study." Journal of Viral Hepatitis, 1999. — Phase III RCT supporting the hepatitis B indication; represents the pivotal human evidence base for chronic HBV treatment.

  2. Goldstein AL, Garaci E. "Combination Therapies Involving Interferon and Thymosin Alpha 1: A Review of Clinical Trials." Annals of the New York Academy of Sciences, 2007. — Review of clinical trial data across hepatitis, cancer, and immune deficiency indications; provides the broadest overview of the clinical evidence base.

  3. Romani L, Bistoni F, Perruccio K, et al. "Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling." Blood, 2004. — Mechanistic study demonstrating Thymosin Alpha-1's activation of dendritic cells through TLR signaling; established the innate-adaptive immune crosstalk mechanism.